1. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry. (December 2022) Authors: Bühler, Klaus; Roeder, Claudia; Schwarze, Juan-Enrique; Lispi, Monica; Allignol, Arthur; Falla, Edel; Lukyanov, Vasily; D´Hooghe, Thomas; Fischer, Robert Journal: Best practice & research Issue: Volume 85(2022)Part B Page Start: 188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers. (December 2022) Authors: Schwarze, Juan-Enrique; Venetis, Christos; Iniesta, Silvia; Falla, Edel; Lukyanov, Vasily; de Agustin Calvo, Elena; D´Hooghe, Thomas; Roeder, Claudia; Matorras, Roberto Journal: Best practice & research Issue: Volume 85(2022)Part B Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PD20 Real-World Evidence To Support Single Arm Trials Of Oncology Interventions: Necessity or 'NICE' (National Institute for Health and Care Excellence) to Have?. (23rd December 2022) Authors: Falla, Edel; Gaultney, Jennifer Journal: International journal of technology assessment in health care Issue: Volume 38(2022)Supplement 1 Page Start: S96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗